Theranos Withdraws FDA Emergency Clearance Request for Zika Test

September 1, 2016

Theranos decided to rescind its request for FDA emergency clearance of its Zika nucleic acid-amplification-based assay.

The diagnostic tool, dubbed minilab, is intended to collect and process small blood samples on a compact testing platform.

The company studied the product in 16 studies across categories, including chemistry, immunochemistry, hematology and molecular biology. — José Vasquez

View today's stories